thioctic acid has been researched along with Idiopathic Parkinson Disease in 18 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism." | 2.50 | Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| " Chronic use of (-)-15 reduced L-DOPA-induced dyskinesia (LID) without attenuating the antiparkinsonian effect." | 1.37 | Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. ( Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S, 2011) |
| " Combination of α-lipoic acid efficiently halting deleterious toxic effects of L-dopa, revealed normalization of catalepsy score in addition to amelioration of neurochemical parameters and apparent preservation of striatal ultrastructure integrity, indicating benefit of both symptomatic and neuroprotective therapy." | 1.37 | Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. ( Abdin, AA; Sarhan, NI, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Wang, M | 1 |
| Zhao, Y | 1 |
| Zhang, Y | 2 |
| Gao, Y | 1 |
| Zhang, X | 2 |
| Yang, G | 1 |
| Zheng, Q | 1 |
| Ma, P | 1 |
| Yang, P | 1 |
| Zhai, S | 2 |
| He, M | 1 |
| Tu, Q | 1 |
| Jiao, L | 2 |
| Ye, L | 1 |
| Feng, Z | 1 |
| Zhang, C | 2 |
| Zhao, H | 1 |
| Zhao, X | 1 |
| Liu, L | 1 |
| Zhang, H | 3 |
| Xuan, M | 1 |
| Guo, Z | 1 |
| Wang, H | 1 |
| Liu, C | 1 |
| Zhou, B | 1 |
| Wen, M | 1 |
| Lin, X | 1 |
| Chen, YH | 1 |
| Gou, Y | 1 |
| Li, Y | 1 |
| Li, HW | 1 |
| Tang, L | 1 |
| Zhang, SF | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Cai, T | 1 |
| Wei, C | 1 |
| Tai, S | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Phillipson, OT | 1 |
| Cortesi, R | 1 |
| Esposito, E | 1 |
| Drechsler, M | 1 |
| Pavoni, G | 1 |
| Cacciatore, I | 1 |
| Sguizzato, M | 1 |
| Di Stefano, A | 1 |
| Lee, SH | 1 |
| Kim, MJ | 1 |
| Kim, BJ | 1 |
| Kim, SR | 1 |
| Chun, S | 1 |
| Ryu, JS | 1 |
| Kim, GS | 1 |
| Lee, MC | 1 |
| Koh, JM | 1 |
| Chung, SJ | 1 |
| Jia, H | 1 |
| Liu, J | 3 |
| Ao, N | 1 |
| Yan, B | 1 |
| Shen, W | 1 |
| Wang, X | 1 |
| Li, X | 1 |
| Luo, C | 1 |
| De Araújo, DP | 1 |
| Lobato, Rde F | 1 |
| Cavalcanti, JR | 1 |
| Sampaio, LR | 1 |
| Araújo, PV | 1 |
| Silva, MC | 1 |
| Neves, KR | 1 |
| Fonteles, MM | 1 |
| Sousa, FC | 1 |
| Vasconcelos, SM | 1 |
| Ye, N | 1 |
| Zhou, S | 1 |
| Guo, L | 1 |
| Zheng, L | 1 |
| Liu, Z | 1 |
| Gao, B | 1 |
| Zhen, X | 1 |
| Zhang, A | 1 |
| Abdin, AA | 1 |
| Sarhan, NI | 1 |
| Zaitone, SA | 1 |
| Abo-Elmatty, DM | 1 |
| Shaalan, AA | 1 |
| Zahid, M | 1 |
| Saeed, M | 1 |
| Yang, L | 1 |
| Beseler, C | 1 |
| Rogan, E | 1 |
| Cavalieri, EL | 1 |
| Bharat, S | 1 |
| Cochran, BC | 1 |
| Hsu, M | 1 |
| Ames, BN | 1 |
| Andersen, JK | 1 |
| Beal, MF | 1 |
3 reviews available for thioctic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Management of the aging risk factor for Parkinson's disease.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb | 2014 |
The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review.
Topics: Animals; Antioxidants; Apoptosis; Disease Progression; Humans; Nerve Degeneration; Oxidative Stress; | 2011 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
1 trial available for thioctic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
Topics: Absorptiometry, Photon; Aged; Analysis of Variance; Anthropometry; Antioxidants; Bone Demineralizati | 2010 |
14 other studies available for thioctic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Alpha lipoic acid ameliorates motor deficits by inhibiting ferroptosis in Parkinson's disease.
Topics: Animals; Iron; Iron Chelating Agents; Neurodegenerative Diseases; NF-E2-Related Factor 2; Parkinson | 2023 |
Neurochemical effects of the R form of α-lipoic acid and its neuroprotective mechanism in cellular models of Parkinson's disease.
Topics: Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Humans; Mitochondria; Neuroprotective A | 2017 |
Alpha Lipoamide Ameliorates Motor Deficits and Mitochondrial Dynamics in the Parkinson's Disease Model Induced by 6-Hydroxydopamine.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apomorphine; Cell Death; Disease Models, Animal; Dopa | 2018 |
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Ind | 2018 |
[Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
Topics: Animals; Cation Transport Proteins; Iron; Iron Regulatory Protein 2; Male; Parkinson Disease; Rats; | 2018 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
L-dopa co-drugs in nanostructured lipid carriers: A comparative study.
Topics: Caffeic Acids; Drug Carriers; Drug Liberation; Half-Life; Humans; Kinetics; Levodopa; Lipids; Micros | 2017 |
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease.
Topics: Acetylcarnitine; alpha-Synuclein; Antioxidants; Drug Synergism; Humans; Mitochondria; Oxidation-Redu | 2010 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Criceti | 2011 |
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Topics: Animals; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Levodopa; Mitochondria; Neurons; N | 2011 |
Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Antioxidants; Dietary Supplements; Dopamine; Dopam | 2012 |
Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease.
Topics: Acetylcysteine; Antioxidants; Benzoquinones; DNA Adducts; Dopamine; Humans; Hydrogen-Ion Concentrati | 2011 |
Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy.
Topics: Animals; Antioxidants; Buthionine Sulfoximine; Cytoplasm; Glutamate-Cysteine Ligase; Glutathione; Mi | 2002 |